Sign in to view content

48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2023

Related

Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Updates from the Field
2025
Systemic Adverse Events in Patients With Diabetes Treated With Intravitreal Antivascular Endothelial Growth Factor Injections
Roomasa Channa, MD
Annual Meeting Talks
2023
Longitudinal Panretinal Leakage Index Assesment in Proliferative Diabetic Retinopathy Treated With Aflibercept From the RECOVERY Study
Amy S. Babiuch, MD, FASRS
Annual Meeting Talks
2019

Category: Diabetic Retinopathy

See more